Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00229437 | Efficacy and Safety Study of TAK-128 in Treating Subjects With Diabetic Peripheral Neuropathy | PHASE2 | COMPLETED | 343 | — | — | Mar 1, 2005 | May 1, 2006 | Feb 28, 2012 | 48 | United States, Canada |
| Arm | Type | Description |
|---|---|---|
| TAK-128 5 mg QD | EXPERIMENTAL | - |
| TAK-128 50 mg QD | EXPERIMENTAL | - |
| TAK-128 100 mg QD | EXPERIMENTAL | - |
| Placebo QD | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| TAK-128 | DRUG | TAK-128 5 mg, tablets, orally, once daily for up to 6 months. |
| Placebo | DRUG | TAK-128 placebo-matching tablets, orally, once daily for up to 6 months. |
Inclusion Criteria: * Female subjects of childbearing potential must be nonpregnant, nonlactating and on an acceptable form of contraception. * The subject has fasting clinical laboratory evaluations within the normal reference range for the testing laboratory, or if not, the results must be deemed...